11P WU-NK-101: An enhanced NK cell therapy optimized for function in the tumor microenvironment (TME)

S Rutella,M.E Mathyer,M Foster,A Carter,K Magee,M Kiebish,J Baughman,M.L Cooper,T.A Fehniger,B.R Tumala,J Ballesteros,P Shah,J Vadakekulathu,M Berrien-Elliott,J Muth,P Comune Pennacchi,V Tolstikov,D Primo,J Gorrochategui,Jan Davidson-Moncada

doi:10.1016/j.annonc.2022.07.039

11P WU-NK-101: An enhanced NK cell therapy optimized for function in the tumor microenvironment (TME)

S Rutella, M.E Mathyer + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.039

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Nottingham Trent University, Precision for Medicine (United States), Washington University in St. Louis

#Efficacy Of Adoptive Cell Therapies #Healthy Donor NK Cells + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The efficacy of adoptive cell therapies against solid tumors has been limited by the immune-suppressive TME, which aids immune escape. WU-NK-101, manufactured using the MONETATM platform, is an NK product derived from healthy donor NK cells that addresses challenges of adoptive cell therapy in the setting of an adverse TME.

Full Text